HC Wainwright & Co. Maintains Buy on Oruka Therapeutics, Raises Price Target to $120
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $75 to $120.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $75 to $120.